BioImpact reports 11.6% stake in Context Therapeutics

BioImpact LLC filed an amended Schedule 13G reporting beneficial ownership of 10,679,391 shares of Context Therapeutics Inc. common stock.

Accepted by SEC EDGAR 02/17/2026 - 04:09 PM EST Learn about SEC filing dates

Rhea-AI Filing Summary

BioImpact LLC filed an amended Schedule 13G reporting beneficial ownership of 10,679,391 shares of Context Therapeutics Inc. common stock. This represents 11.6% of the outstanding common shares. BioImpact has sole voting and sole dispositive power over all reported shares, with no shared power.

The filing states the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of Context Therapeutics, other than activities solely in connection with a nomination under Rule 240.14a-11.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What stake in Context Therapeutics (CNTX) does BioImpact LLC report?

BioImpact LLC reports beneficial ownership of 10,679,391 shares of Context Therapeutics common stock, representing 11.6% of the class. This holding gives BioImpact a significant minority stake with sole voting and dispositive power over all reported shares.

What type of filing did BioImpact LLC submit for Context Therapeutics (CNTX)?

BioImpact LLC submitted an amended Schedule 13G/A for Context Therapeutics. This filing is used to report passive ownership of more than 5% of a company’s stock, indicating a sizeable position without an activist intent to influence corporate control.

Does BioImpact LLC seek to influence control of Context Therapeutics (CNTX)?

BioImpact LLC certifies the shares were acquired and are held in the ordinary course of business, not to change or influence control of Context Therapeutics. The filing allows only activities connected with a nomination under Rule 240.14a-11 as an exception.

What voting and dispositive powers does BioImpact LLC have over CNTX shares?

BioImpact LLC reports sole voting power and sole dispositive power over 10,679,391 Context Therapeutics shares, with no shared voting or dispositive authority. This means BioImpact alone decides how these shares are voted and whether, when, and how they are sold.

When was the ownership event for BioImpact LLC’s CNTX stake dated?

The ownership information for BioImpact LLC’s stake in Context Therapeutics is dated as of December 31, 2025. This date anchors when the 10,679,391 shares and the 11.6% beneficial ownership level were calculated for purposes of the Schedule 13G/A filing.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

(Amendment No. 1)

Context Therapeutics Inc.

(Name of Issuer)

Common Stock, par value $0.001 per share

(Title of Class of Securities)

21077P108

(CUSIP Number)

12/31/2025

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

SCHEDULE 13G

CUSIP No. 21077P108

1

Names of Reporting Persons

MPM BioImpact LLC

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 10,679,391.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 10,679,391.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

10,679,391.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

11.6 %

12

Type of Reporting Person (See Instructions)

IA

SCHEDULE 13G

Item 1.
(a)	Name of issuer: Context Therapeutics Inc.
(b)	Address of issuer's principal executive offices: 2001 MARKET STREET, SUITE 3915 UNIT #15, PHILADELPHIA, PA, 19103.
Item 2.
(a)	Name of person filing: MPM BioImpact LLC
(b)	Address or principal business office or, if none, residence: 399 Boylston Street, Suite 1100 Boston, MA 02116
(c)	Citizenship: Delaware
(d)	Title of class of securities: Common Stock, par value $0.001 per share
(e)	CUSIP No.: 21077P108
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: 10,679,391
(b)	Percent of class: 11.6%
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: 10,679,391
	(ii) Shared power to vote or to direct the vote: 0
	(iii) Sole power to dispose or to direct the disposition of: 10,679,391
	(iv) Shared power to dispose or to direct the disposition of: 0
Item 5.	Ownership of 5 Percent or Less of a Class.
	Not Applicable
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	Not Applicable
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	Not Applicable
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

MPM BioImpact LLC

Signature:	Christopher Wolf
Name/Title:	Chief Financial Officer
Date:	02/17/2026